

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

NCT02870244

Status	RECRUITING
Phase	Phase 1
Sponsor	Loyola University
Enrollment	18 participants

Plain Language Summary

This study tests a new type of immune cell therapy for advanced melanoma (skin cancer that has spread), where patients' own immune cells are engineered in a lab to better find and attack cancer cells before being given back to the patient.

****You may be eligible if...****

- You have been diagnosed with advanced melanoma that has spread (metastatic melanoma)
- You are 18 years of age or older
- You are in good physical condition (able to perform normal daily activities)
- Your cancer can be measured or seen on scans

****You may NOT be eligible if...****

- You are younger than 18 years
- You are in poor overall physical health
- Your cancer cannot be measured or tracked

This is an experimental therapy — researchers are studying whether engineered immune cells can safely and effectively treat melanoma that has spread. Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (12)

- Patients must have a diagnosis of metastatic melanoma which is evaluable either clinically or radiologically.
- Patients must be 18 years of age or older.
- Patients must consent to be in the study and must have signed and dated an approved consent form, which conforms to federal and institutional guidelines.
- Patients must have a performance status (PS) of 0 or 1 ECOG PS scale.
- Patients must have the ability to provide written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time.

... and 7 more (see full listing online)

Exclusion (16)

- Special classes of subjects such as fetuses, pregnant women, children, prisoners, institutionalized individuals, or others who are likely to be vulnerable.
- ECOG performance status of 2 or greater.
- Patients with a history metastatic melanoma involving the brain will be excluded if they have active disease or have had active disease within the prior three months that was not controlled with surgery or radiotherapy.
- Patients taking steroids for disease control or pain management

• Patients must not be pregnant or nursing because of the potentially harmful effects of these agents on a developing fetus. Women of reproductive potential must have agreed to use an effective contraceptive method.

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

... and 11 more (see full listing online)

Locations (1 total)

Loyola University Medical Center, Maywood, Illinois, United States

<https://clinicaltrials.gov/study/NCT02870244>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by ClinicalTrialsFinder.org.